Lead Sponsor

Hoffmann-La Roche

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year for at least 30 days after the last fluorescein dye administration
•The study is being conducted in participants with GA in both Study Eye and Non-Study Eye (bilateral GA) with no evidence of prior or active choroidal neovascularization (CNV)

•Previous participation in any studies of investigational drugs for GA or dry AMD (except for studies of vitamins and minerals)
•GA in either eye due to causes other than AMD
•History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD
•Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy
•Any ocular or systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments
•Requirement for continuous use of therapy indicated in Prohibited Therapy in the study Protocol

Related studies

NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07230834 · Geographic Atrophy (GA)

NCT07441642 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07144137 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT06779773 · Geographic Atrophy, Macular Degeneration

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration